Thrombolysis with Recombinant Human Prourokinase 4.5 –6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial

ConclusionIn the 4.5 –6 h time window, more than 60% of patients at either dose of rhPro-UK (50 mg or 35 mg) achieved functional independence at 90 days without increased mortality and sICH risk. Thus, intravenous rhPro-UK was effective and safe for patients with AIS within 4.5–6 h after stroke onset. While no signi ficant differences were identified between different dosages of rhPro-UK regarding clinical outcomes, it is a logical step to further test the safety and efficacy of the low dose of rhPro-UK in a well-powered phase III study.Trial Registrationhttp://www.chictr.org.cn. Identifier: ChiCTR1800016519. Date of registration: 6 June 2018.
Source: CNS Drugs - Category: Neurology Source Type: research